



East Region Formulary



Summary of updates to East Region Formulary (ERF) website.

The purpose of this summary is to detail the main changes to the ERF. The website chapters should be referred to for full details. All of the amendments detailed appear on the new website platform which can be found here: formulary.nhs.scot/east/.

Note that there are a few remaining paediatric chapters on the new website platform for the East Region Formulary that are old Lothian recommendations awaiting review by representatives from the region.

TIPS: See the 'History Notes' for a brief description of the change and the date of the change, as in the example below.

A Treatment of pain in palliative care

Prescribing Notes:

- The [National Palliative Care Guidelines](#) have been developed by a multidisciplinary group of professionals working in the community, hospital and specialist palliative care services throughout Scotland and are used in all Scottish Health Boards.
- The guidelines reflect a consensus of opinion about good practice in the management of adult patients with a life limiting illness.
- Guidelines on individual symptoms are available. Each page has some introductory information, links to related guidelines and web resources. The individual guidelines are in PDF format and can be downloaded or printed off.

History Notes

| | |
|------------|------------------------------------|
| 20/10/2020 | Content migrated from LJF website. |
|------------|------------------------------------|

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|----------------|----------------|--|---------------------------|--|--|---------------------|
| Anaesthesia | Adult | ERF | General anaesthesia | Induction and maintenance of anaesthesia | UM flag added to Thiopental 500mg/20ml solution for injection pre-filled syringes | ERWG September 2024 |
| Cardiovascular | Adult | ERF | Cardiovascular conditions | Angina | Total pathway review: <ul style="list-style-type: none"> • Updated Guidance links • Pathway 2 – ‘Regular treatment of angina’ - Removal of Isosorbide mononitrate and inclusion of Bisoprolol as first-line treatment option • Nicorandil and Ivabradine included as second-line treatment options • Updated prescribing information | ERFC October 2024 |
| CNS | Adult | ERF | Epilepsy conditions | Epilepsy treatments – specialist list | SUO flag added to Fenfluramine | ERWG September 2024 |
| CNS | Child | ERF | Nicotine dependence | Smoking cessation treatment | Link removed to Varenicline MSAN (new generics available Aug 2024, PGDs being reviewed and updated) | ERWG September 2024 |
| CNS | Adult | ERF | Multiple sclerosis | Treatment of active relapsing remitting multiple sclerosis | Diroximel fumarate moved to second-line treatment option | ERFC October 2024 |

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|------------------|----------------|--|--|---|--|---------------------|
| CNS | Adult | ERF | Psychoses and related disorders | Bipolar disorder > Maintenance treatment of bipolar disorder | MHRA DSU September 2024 – updated prescribing notes | ERFC October 2024 |
| CNS | Child | ERF | Epilepsy syndromes and epilepsy conditions | Various paediatric epilepsy pathways, Dravet Syndrome and Lennox-Gastaut Syndrome | MHRA DSU September 2024 – updated prescribing notes | ERFC October 2024 |
| Endocrine | Adult | ERF | Diabetes | Diabetes Mellitus – type 2 | Pathway 3 ‘3 rd line medicines treatment’ – Inclusion of Tirzepatide SMC2633, brand names added for biologics, and addition of link to MSAN for Tresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pens (also added in Type 1 Diabetes Mellitus pathway) | ERFC October 2024 |
| Endocrine | Adult & Child | ERF | Diabetes Mellitus | Diabetes Mellitus - diagnostic and monitoring agents | Inclusion of FreeStyle Libre 2 Plus and updated prescribing notes | ERFC October 2024 |
| Gastrointestinal | Adult | ERF | Formulary Decision Only | Formulary Decision Only | Rifaximin: Targaxan (SMC 893/13) – brand name removed and changed to generic name | ERWG September 2024 |
| Gastrointestinal | Child | ERF | Bowel disorders | Crohn’s disease > Severe active or active fistulising Crohn’s disease | Addition of Ustekinumab biosimilars and updated prescribing notes | ERFC October 2024 |

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|------------------|----------------|--|-----------------|---|---|---------------------|
| Gastrointestinal | Adult | ERF | Bowel disorders | Crohn's disease > Severe active or active fistulising Crohn's disease | Addition of Ustekinumab biosimilars and updated prescribing notes | ERFC October 2024 |
| Gastrointestinal | Adult | ERF | Liver disorders | Hepatic encephalopathy > Prophylaxis of hepatic encephalopathy | Pathway moved from Colonic disorder > Constipation to new pathway Liver disorders > Hepatic encephalopathy > Prophylaxis of hepatic encephalopathy – no new medicines, order of choices remain the same | ERFC October 2024 |
| Infection | Adult | ERF | Respiratory | Pertussis - Treatment of pertussis and Prophylaxis of pertussis | New pathway content agreed | ERWG September 2024 |
| Infection | Adult | ERF | Respiratory | Bronchitis > Treatment of acute cough and bronchitis | Erythromycin included as antibiotic option for penicillin allergy in pregnancy | ERWG September 2024 |
| Infection | Adult | ERF | Respiratory | Pneumonia – community acquired (CAP): Treatment at home – CRB-65 score of 0 and Treatment at home – CRB-65 score of 1-2 | Erythromycin included as antibiotic option for penicillin allergy in pregnancy | ERWG September 2024 |
| Infection | Adult | ERF | Wound and Skin | Cellulitis > Treatment of cellulitis (no systemic symptoms) | Inclusion of Clindamycin 150mg capsules as second-line treatment option, and revised prescribing notes | ERWG September 2024 |

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|------------------------------------|----------------|--|------------------------------------|---|---|---------------------|
| Infection | Adult & Child | ERF | Gastrointestinal | Giardiasis > Adult – Treatment of giardiasis and Child – Treatment of giardiasis | Prescribing information updated | ERWG September 2024 |
| Infection | Adult & Child | ERF | Ear, nose, and oropharynx | Oral candidiasis > Treatment of oral candidiasis | Nystatin sugar free suspension discontinued - changed to Nystatin oral suspension | ERWG September 2024 |
| Infection | Child | ERF | Respiratory | Pertussis > Treatment of Pertussis | Follow up window change from 21 to 14 days (current UKHSA guidance in period of increased transmission) | ERWG September 2024 |
| Musculoskeletal and joint diseases | Adult | ERF | Musculoskeletal and joint diseases | Psoriatic Arthritis > Treatment of Psoriatic arthritis with biologics and targeted synthetic DMARDs | Addition of ustekinumab biosimilars: Pyzchiva 45mg/0.5ml solution for injection pre-filled syringes Pyzchiva 90mg/1ml solution for injection pre-filled syringes Wezenla 45mg/0.5ml solution for injection vials Wezenla 45mg/0.5ml solution for injection pre-filled syringes Wezenla 90mg/1ml solution for injection pre-filled syringes | ERFC October 2024 |
| Nutrition & Blood | Adult | ERF | Nutrition | Coeliac disease | Pack size change | ERWG September 2024 |

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|-------------|----------------|--|-----------------------------------|--|---|------------------------|
| Respiratory | Adult & Child | ERF | Respiratory disorders | Asthma | New pathway: Adult pathway 1: Anti-inflammatory reliver (AIR) therapy Child pathway 1: Anti-inflammatory reliver (AIR) therapy Addition of Symbicort SMC2622 | ERWG September 2024 |
| Respiratory | Child | ERF | Respiratory disorders | Allergy > Pathway 3: Allergic emergencies | Adrenaline dose changed from 'See Resus guidance' in prescribing notes to 'See BNFc for dose'. | ERWG September 2024 |
| Skin | Adult | ERF | Specialist dermatology management | Hidradenitis suppurativa > Pathway 1: Treatment of Hidradenitis suppurativa | Addition of Secukinumab: Cosentyx (SMC2592) | ERWG September 2024 |
| Skin | Adult | ERF | Skin conditions | Psoriasis > 'Biologic treatment of chronic plaque psoriasis', 'Biologic treatment of psoriasis with psoriatic arthritis', and 'Biologic treatment of chronic plaque psoriasis with inflammatory bowel disease' | Addition of Ustekinumab biosimilars: Pyzchiva 45mg/0.5ml solution for injection pre-filled syringes Pyzchiva 90mg/1ml solution for injection pre-filled syringes Wezenla 45mg/0.5ml solution for injection vials Wezenla 45mg/0.5ml solution for injection pre-filled syringes Wezenla 90mg/1ml solution for injection pre-filled syringes | ERFC October 2024 |

| Chapter | Adult or Child | ERF or LJF (until future ERF chapter review) | Group | Condition | New content | Month of ERWG/ ERFC |
|------------|----------------|--|------------------|--|---|---------------------|
| Skin | Child | ERF | Skin conditions | Psoriasis > ‘Biologic treatment of chronic plaque psoriasis’ | Addition of Ustekinumab biosimilars: Pyzchiva 45mg/0.5ml solution for injection pre-filled syringes Pyzchiva 90mg/1ml solution for injection pre-filled syringes Wezenla 45mg/0.5ml solution for injection vials Wezenla 45mg/0.5ml solution for injection pre-filled syringes Wezenla 90mg/1ml solution for injection pre-filled syringes | ERFC October 2024 |
| Wound Care | Adult | ERF | Wound management | Wound management products > Pathway 11: Foam dressings – with border | Correction to information note that stated ‘without border’ | ERWG September 2024 |

To review Formulary Decisions noted at the East Region Formulary Committee refer to the [Minutes of East Region Formulary Committee](#) or alternatively search [Formulary Decisions](#) with the relevant start date. See example below:

Lothian Joint Formulary

Search

NHS
SCOTLAND

Therapeutic AreasMedicines A-ZConditions A-ZMedicine CategoriesFormulary Decisions

Home > Formulary Decisions

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Generic medicine name

Medicine brand name

Therapeutic area

Please select...

Start date

Wednesday December 16, 2020

End date

Source

Please select...

2020

December

| | | | | | | |
|----|----|----|----|----|----|----|
| S | M | T | W | T | F | S |
| | | 1 | 2 | 3 | 4 | 5 |
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | | |

Lothian

Healthier
Scotland
Scottish
Government

NHS
SCOTLAND

Help
Upd
Privacy and cookies
Terms and conditions
Contact us
© Copyright